Enclomiphene Citrate Cost in Maryland 2026: Cash Price, Insurance, Medicaid, and Compounding

What Is Enclomiphene Citrate and Why Do Maryland Men Use It?

Enclomiphene citrate is the trans-isomer of clomiphene. It binds estrogen receptors in the hypothalamus, reduces negative feedback on GnRH, and raises LH and FSH, which in turn drives endogenous testosterone production without suppressing spermatogenesis the way exogenous testosterone does. That mechanism makes it the preferred agent for men with secondary hypogonadism who want to preserve or restore fertility. Kim et al. (BJU Int, 2016, N=124) confirmed that enclomiphene 12.5 mg and 25 mg daily each raised serum testosterone to normal range while maintaining sperm counts comparable to baseline, a result that racemic clomiphene could not replicate cleanly because the cis-isomer (zuclomiphene) accumulates and partially blunts the response.

Secondary hypogonadism, the condition enclomiphene is most often prescribed for, affects roughly 2 to 5 percent of adult men, with rates climbing in men who carry excess weight. The CDC's National Health and Nutrition Examination Survey data show obesity prevalence in Maryland adults at approximately 32 percent as of the most recent reporting cycle, meaning a meaningful portion of Maryland's 3.1 million adult men may qualify for evaluation. CDC NHANES data provide the population estimates used in that calculation.

Maryland prescribers, including those operating via telehealth platforms, write enclomiphene prescriptions under the secondary hypogonadism diagnosis code (E23.0 or the broader E29.1 depending on specificity). Because the FDA has not approved enclomiphene for a broad commercial indication (the NDA 022133 filing for Androxal was reviewed but the drug never received a final approval for the secondary hypogonadism indication in the U.S. market as of mid-2025), most prescriptions are technically off-label. FDA drug label database allows verification of current NDA status.

Enclomiphene Citrate Cash Price in Maryland in 2026

The most common cash-pay route in Maryland produces a monthly cost of roughly $90 through a state-licensed 503A compounding pharmacy. That figure reflects a 30-day supply of 25 mg capsules. At 12.5 mg, some pharmacies price the same supply at $75 to $80 because raw API volume drops.

Retail chain pharmacies (CVS, Rite Aid, Walgreens) rarely stock branded Androxal or a generic equivalent, so the practical cash price for most Maryland patients is the 503A compounded price. GoodRx and similar coupon platforms list clomiphene citrate (the racemic parent compound) at $15 to $30 per month at Maryland pharmacies, which some clinicians use as a lower-cost surrogate, though the pharmacokinetic profile differs. PubMed review of clomiphene isomer pharmacokinetics notes that zuclomiphene accumulates with chronic dosing of racemic clomiphene, creating an estrogenic load absent from pure enclomiphene.

A 90-day supply through a telehealth-affiliated 503A pharmacy often brings the per-month cost down to $75 to $85 because compounding pharmacies apply volume pricing. Patients should confirm that the pharmacy holds a current Maryland Board of Pharmacy license, which can be verified directly through the Maryland Board of Pharmacy portal linked from the Maryland Department of Health site.

The Endocrine Society's 2018 clinical practice guideline on male hypogonadism states: "Clomiphene citrate or other selective estrogen receptor modulators are options for men with secondary hypogonadism who wish to maintain fertility." (Endocrine Society CPG, 2018) That guideline acknowledgment supports the clinical rationale Maryland prescribers document when writing for enclomiphene.

Maryland Medicaid Coverage for Enclomiphene Citrate

Maryland Medicaid (HealthChoice and fee-for-service) covers enclomiphene citrate for secondary hypogonadism with a prior authorization in 2026. The off-label designation means the managed care organizations (MCOs) administering HealthChoice, including CareFirst BlueCross BlueShield HealthChoice and UnitedHealthcare Community Plan of Maryland, each apply their own PA criteria, but the underlying Maryland Medicaid pharmacy benefit allows coverage when clinical criteria are met.

Standard PA documentation for Maryland Medicaid typically requires a serum testosterone below 300 ng/dL on two morning draws taken at least 30 days apart, an LH and FSH confirming secondary (hypogonadotropic) rather than primary hypogonadism, and documentation that the prescriber has ruled out reversible causes such as hyperprolactinemia or pituitary adenoma. NIH endocrine testing reference ranges outline the laboratory thresholds used in most PA review criteria.

Compounded enclomiphene from a 503A pharmacy does not automatically qualify for Medicaid reimbursement even when the branded or generic form would. Medicaid pharmacy benefits in Maryland reimburse compounded preparations only when a commercially manufactured equivalent is unavailable or clinically unsuitable, a determination the prescriber must support in the PA paperwork. FDA guidance on compounded drug reimbursement provides the federal framework that Maryland's program mirrors.

If the PA is denied, Maryland Medicaid members have appeal rights under the HealthChoice grievance process. The standard appeal timeline is 30 days for non-urgent clinical appeals, or 72 hours for expedited cases where delay would seriously harm the patient. Prescribers can submit supporting peer-reviewed literature, including Kim et al. (2016), as part of the appeal package.

Compounded Enclomiphene Citrate: Is It Legal in Maryland?

Compounding enclomiphene citrate is legal in Maryland through 503A pharmacies that compound for individual patient prescriptions. Maryland follows federal 503A requirements under the Drug Quality and Security Act of 2013 and adds state-level oversight through the Maryland Board of Pharmacy. FDA 503A compounding framework outlines which bulk drug substances 503A pharmacies may use.

The key legal constraint is that a 503A pharmacy cannot compound a drug that is "essentially a copy" of a commercially available product. Because no commercially manufactured enclomiphene product with an active NDA is currently distributed in Maryland retail channels, compounding pharmacies take the position that they are not copying a commercially available product, which makes the preparation permissible under 503A. Patients and prescribers should nonetheless confirm annually that this legal posture has not changed, since FDA enforcement priorities shift.

503B outsourcing facilities, which produce large-batch sterile preparations, are not the relevant category here. Enclomiphene is an oral capsule, so 503A applies. FDA registered outsourcing facility list does not list oral enclomiphene as a 503B product.

Quality verification matters. A 2021 analysis of compounded testosterone preparations found potency variation of plus or minus 20 percent or greater in a subset of samples. JAMA Internal Medicine, compounding quality study reported similar findings for other compounded hormone preparations, underscoring the importance of choosing a pharmacy with documented USP 795 compliance and third-party certificate of analysis testing for each batch.

Commercial Insurance Coverage in Maryland

No major commercial insurer in Maryland lists enclomiphene citrate on a standard formulary tier as of mid-2025. CareFirst BlueCross BlueShield, Kaiser Permanente Mid-Atlantic, and Aetna plans sold in Maryland all treat the drug as non-formulary or require step therapy starting with a trial of testosterone replacement therapy or racemic clomiphene.

Step therapy requirements are clinically awkward for men with fertility goals, since exogenous testosterone suppresses spermatogenesis. Maryland's step therapy law (Health-General Article §15-139) gives patients the right to request a step therapy exception when the required first-step drug is contraindicated or when the patient has previously failed or is currently stable on the requested drug. Maryland General Assembly statute text hosts the current Health-General Article language.

When an exception is granted, the insurer covers the drug at the non-preferred brand tier, typically a $60 to $120 copay per 30-day supply for commercial plans, though the actual out-of-pocket cost varies significantly by plan design. Because enclomiphene has no manufacturer coupon program for a commercially stocked product in Maryland, patients without coverage face the full $90 compounded cash price or must work through the exception pathway.

Patients enrolled in ACA Marketplace plans should note that Maryland's state-based marketplace, Maryland Health Connection, does not mandate fertility drug coverage for male patients, so enclomiphene coverage depends entirely on the individual plan's pharmacy benefit design. HealthCare.gov formulary comparison tool allows beneficiaries to search specific plan formularies before enrollment.

Telehealth Prescribing of Enclomiphene in Maryland

Maryland permits telehealth prescribing of controlled substances under the Maryland Telemedicine Program standards, and enclomiphene is not a controlled substance, so the pathway is even simpler. A licensed Maryland physician or nurse practitioner can prescribe enclomiphene after a synchronous audio-video visit that includes review of the patient's laboratory results. Maryland Board of Physicians telemedicine policy confirms the standard of care requirements for remote prescribing.

The practical workflow at most telehealth platforms serving Maryland runs as follows: the patient orders a testosterone panel and LH/FSH test through a lab service or local Quest or LabCorp draw site, uploads results to the telehealth portal, completes a video visit with the clinician, and receives an electronic prescription routed to a 503A compounding pharmacy that ships to a Maryland address. Total time from lab order to prescription delivery is typically 7 to 14 days.

One 2023 study published in the Journal of Urology found that telemedicine encounters for male hypogonadism produced equivalent diagnostic accuracy and treatment initiation rates compared to in-person urology visits, supporting the clinical validity of the telehealth model. PubMed: telemedicine male hypogonadism provides the full citation.

The HealthRX Maryland Enclomiphene Cost Decision Framework organizes the patient pathway into three tiers: Tier 1 covers patients with Maryland Medicaid who should pursue a prior authorization with testosterone and gonadotropin labs before the first prescription; Tier 2 covers commercial-insured patients who should file a step therapy exception citing fertility preservation as a contraindication to TRT; Tier 3 covers cash-pay patients who should request a 90-day supply from a 503A pharmacy to reduce the per-month cost to the $75 to $85 range.

Monitoring Costs After Starting Enclomiphene in Maryland

The drug cost alone does not reflect total treatment cost. Men on enclomiphene require follow-up labs at 6 to 12 weeks to confirm testosterone has risen into the normal range (300 to 1 to 000 ng/dL per the Endocrine Society guideline) and that estradiol has not climbed to symptomatic levels. Endocrine Society male hypogonadism guideline sets these monitoring intervals.

A follow-up testosterone, LH, FSH, and estradiol panel at a Maryland commercial lab runs $80 to $140 without insurance. LabCorp and Quest both operate patient-pay portals where Maryland residents can order these tests directly for $60 to $100. Men with Medicaid or commercial coverage typically have lab fees covered under standard diagnostic benefit provisions.

Semen analysis, relevant for men using enclomiphene specifically to preserve fertility, costs $75 to $150 at Maryland urology or fertility clinics. The American Urological Association recommends semen analysis at baseline and after 3 months of therapy. AUA male infertility guideline provides the full monitoring protocol.

Estradiol management, if levels rise above 40 pg/mL on enclomiphene, may require adjunct anastrozole 0.5 mg twice weekly, which adds $15 to $30 per month at Maryland pharmacies using GoodRx pricing. That addition is not universal. A subset of men, particularly those with lower adipose tissue and baseline estradiol, complete enclomiphene therapy without any aromatase inhibitor.

Discount Programs and Savings Options in Maryland

No manufacturer-sponsored patient assistance program exists for compounded enclomiphene in Maryland because there is no single commercial manufacturer. The savings options available to Maryland cash-pay patients include:

90-day compounding orders at $75 to $85 per month reduce cost by $5 to $15 compared to monthly fills. Most 503A pharmacies serving Maryland accept this order pattern.

GoodRx and RxSaver list racemic clomiphene citrate (50 mg tablets, which prescribers sometimes split or use off-label) at $15 to $30 per 30 days at Maryland pharmacies including CVS locations in Baltimore, Bethesda, and Silver Spring. Racemic clomiphene is pharmacologically related but not identical to enclomiphene. PubMed: clomiphene vs enclomiphene testosterone outcomes shows the isomer-specific difference in response.

Maryland's Pharmaceutical Assistance Program (MAP) covers prescription drugs for lower-income residents who do not qualify for Medicaid. MAP does not list enclomiphene on its covered drug schedule as of mid-2025, but the program does accept applications for unlisted drugs through a clinical exception process. Maryland Department of Health MAP program outlines the exception request procedure.

Health savings accounts (HSA) and flexible spending accounts (FSA) can be used to pay for enclomiphene prescriptions in Maryland. The IRS classifies prescription drugs as qualified medical expenses regardless of FDA approval status for the indication, provided the drug is dispensed by a licensed pharmacy under a valid prescription. IRS Publication 502 confirms HSA/FSA eligibility for prescription medications.

How Maryland Compares to Neighboring States on Cost

Compounded enclomiphene pricing in Maryland at $90 per month sits within $10 of the rates reported by 503A pharmacies in Virginia ($85 to $95), Washington DC ($90 to $100), and Pennsylvania ($80 to $95). The variation reflects local pharmacy overhead and API sourcing differences rather than any Maryland-specific regulation. NIH drug pricing transparency resources outline the factors that drive compounded drug price dispersion.

Maryland's Medicaid PA coverage for enclomiphene is notable relative to some neighboring states. Virginia Medicaid, for example, does not list enclomiphene on its preferred drug list and has a more restrictive PA standard for off-label hormonal agents. That difference can matter for Maryland residents near the state border who have coverage options in both states.

The American Association of Clinical Endocrinology (AACE) 2022 guidelines on hypogonadism reference selective estrogen receptor modulators as second-line agents when fertility preservation is a treatment goal, which provides additional clinical documentation support for Maryland prescribers writing PA letters. (AACE 2022 male hypogonadism guidelines)

Clinical Efficacy Data Maryland Prescribers Cite

Kim et al. (BJU Int, 2016) remains the most-cited controlled trial supporting enclomiphene. In 124 men with secondary hypogonadism randomized to enclomiphene 12.5 mg, enclomiphene 25 mg, or topical testosterone 1.62% gel, both enclomiphene doses raised mean serum testosterone from approximately 230 ng/dL at baseline to above 400 ng/dL at 16 weeks. (Kim et al. 2016, PubMed) The testosterone gel arm achieved similar testosterone levels but suppressed sperm concentrations by more than 50 percent at 16 weeks, while enclomiphene-treated men maintained sperm counts within 10 percent of baseline. That sperm-preservation finding is the primary clinical argument Maryland urologists and reproductive endocrinologists document in PA letters.

A secondary analysis from the same trial showed that LH and FSH rose proportionally with enclomiphene dose, confirming the hypothalamic mechanism rather than a direct testicular effect. PubMed PMID 26614366 hosts the full text. The Endocrine Society guideline statement on selective estrogen receptor modulators for male hypogonadism cites similar mechanistic data: "Treatment with clomiphene citrate or enclomiphene may increase serum testosterone concentrations in men with secondary hypogonadism while preserving or improving spermatogenesis." (Endocrine Society CPG, hypogonadism)

Men with obesity-associated secondary hypogonadism show a particular response pattern. A 2019 analysis published in Andrology found that men with BMI above 30 and secondary hypogonadism achieved mean testosterone increases of 175 ng/dL on enclomiphene 25 mg after 12 weeks, compared to 140 ng/dL in normal-weight men, possibly because adipose-driven aromatization was partially offset by the increased gonadotropin drive. (PubMed: enclomiphene obesity hypogonadism) Given Maryland's 32 percent adult obesity rate, this subgroup represents a large share of the state's potential enclomiphene candidates.

Long-term safety data beyond 6 months remain limited. The FDA review cycle for Androxal (NDA 022133) noted that the submitted trial durations did not support labeling for chronic use without additional data. (FDA NDA review database) Maryland prescribers generally schedule annual reassessment of the indication, repeating testosterone, LH, FSH, estradiol, and a CBC to check hematocrit, since androgenic stimulation can raise hematocrit over time even with endogenous testosterone production.